Chinese CRO/CDMO supplying fine chemical building blocks and custom synthesis for drug discovery.
Chinese CRO/CDMO supplying fine chemical building blocks and custom synthesis for drug discovery.
Sells a catalog of many small-molecule building blocks in small quantities to drug-discovery labs, then follows promising ones into larger custom-made quantities as drugs advance through trials, giving it work from discovery through to commercial supply. Overseas customers account for the bulk of sales.
In one line: A China-based pharma building-blocks CDMO.
Moat: narrow (scale, customer qualification). Broad building-block catalog and qualified GMP capacity are costly to replicate.
Headquarters: Nanjing, China · Employees: 2,593
Size PharmaBlock Sciences (Nanjing) (300725.SZ) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.36B, the 1658th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥40.06 on 18 Nov 2026.
Performance Over six months the shares gained 5.4%, against -17.4% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 10.6% over the last twelve months (peer median +4.9%); the operating margin is 10.7% (peer median 7.6%).
Valuation It trades at 37.5× forward earnings against a peer median of 19.1× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.6 points below its cost of capital (11.7% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.19B | CN¥1.96B | CN¥1.68B | CN¥1.72B | CN¥1.58B |
| Revenue growth | — | +17% | -2% | +9% | — |
| Gross profit | CN¥801M | CN¥566M | CN¥598M | CN¥689M | CN¥675M |
| EBITDA | n/a | CN¥332M | CN¥357M | CN¥381M | CN¥375M |
| Net income | CN¥222M | CN¥184M | CN¥220M | CN¥197M | CN¥314M |
| Free cash flow | CN¥46.9M | CN¥571M | CN¥231M | -CN¥41.1M | -CN¥291M |
| Capital expenditure | CN¥376M | CN¥140M | CN¥118M | CN¥316M | CN¥558M |
| Total debt | CN¥95.6M | CN¥181M | CN¥1.46B | CN¥1.83B | CN¥1.71B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300725.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.9% | -0.5% | 5th lowest of 21 |
| 6-month return | +5.4% | -17.4% | 7th highest of 21 |
| Distance from 52-week high | -30.4% | -37.8% | 8th highest of 21 |
| Revenue growth (TTM) | +10.6% | +4.9% | 8th highest of 21 |
| Operating margin | 10.7% | 7.6% | 6th highest of 21 |
| Forward P/E | 37.5× | 19.1× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 24.2% | 6.6% | 4th most demanding of 17 |
| Growth delivered (Del g) | +14.1% | +9.4% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | +10.2 pp | -5.7 pp | 5th most demanding of 17 |
| ROIC minus cost of capital | -3.6 pp | +0.6 pp | 7th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PharmaBlock Sciences (Nanjing) 300725.SZ | China | $1.36B | +5% | +11% | 11% | 37.5× | 24.2% | +14.1% |
| CRA International CRAI | United States | $1.35B | +46% | +13% | 10% | 23.3× | 6.6% | +8.1% |
| SBS 2384.T | Japan | $1.35B | +26% | +17% | 5% | 13.9× | -4.7% | +13.8% |
| Derichebourg DBG.PA | France | $1.37B | -18% | -3% | 5% | 8.8× | 6.7% | +6.3% |
| China National Electric Apparatus Research Institute 688128.SS | China | $1.35B | -17% | +8% | 11% | 14.7× | 3.2% | +13.5% |
| China Security 600654.SS | China | $1.34B | -31% | -30% | -1% | n/a | 56.0% | +0.4% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -41% | +22% | 2% | 43.1× | n/a | n/a |
| Clarivate CLVT | United States | $1.38B | -12% | -9% | 8% | 3.5× | 13.2% | +14.4% |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.38B | -22% | +10% | 33% | n/a | 4.5% | +18.7% |
| Shanghai Medicilon 688202.SS | China | $1.39B | +8% | +42% | -2% | 85.1× | n/a | n/a |
| Shenzhen Ampron Technology 301413.SZ | China | $1.40B | -28% | +11% | 2% | 387.2× | n/a | n/a |
| Offcn Education Technology 002607.SZ | China | $1.40B | -40% | -2% | 13% | 34.7× | 15.7% | -27.6% |
| ICF International ICFI | United States | $1.40B | +14% | -5% | 8% | 10.4× | -2.5% | +4.4% |
| TKC 9746.T | Japan | $1.31B | +22% | +5% | 20% | 19.1× | -10.1% | +5.7% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.31B | -30% | +20% | 3% | 137.1× | 42.5% | +26.7% |
| AFRY AFRY.ST | Sweden | $1.42B | +5% | -4% | 7% | 12.5× | -2.2% | +6.3% |
| Yangzhou Tinfulong 603406.SS | China | $1.42B | -29% | -4% | 12% | n/a | 6.1% | +10.6% |
| Shanghai Foreign Service 600662.SS | China | $1.42B | -14% | +1% | 2% | 13.2× | n/a | n/a |
| Moltiply MOL.MI | Italy | $1.45B | +12% | +20% | 16% | 14.0× | 10.9% | +21.0% |
| Visual China 000681.SZ | China | $1.46B | -34% | -9% | 4% | 37.6× | 57.8% | +6.5% |
| Suzhou Recodeal Interconnect System 688800.SS | China | $1.26B | -68% | +5% | 9% | 31.0× | 22.7% | +38.9% |